Miyoshi Yasuhide, Tsutsumi Sohgo, Kawahara Takashi, Yasui Masato, Uemura Koichi, Yoneyama Shuko, Yokomizo Yumiko, Hayashi Narihiko, Yao Masahiro, Uemura Hiroji
Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.
Department of Urology Yokohama City University School of Medicine Yokohama Japan.
BJUI Compass. 2020 Sep 5;2(1):24-30. doi: 10.1002/bco2.43. eCollection 2021 Jan.
The objective of this study was to evaluate automated bone scan index (aBSI) as a prognostic biomarker for overall survival (OS) in bone-metastatic, castration-resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).
We identified 42 men treated with Ra-223 for mCRPC. We investigated aBSI as an independent prognostic factor by multivariate analysis. Moreover, we evaluated the prognostic value of the aBSI after 12 weeks after the first cycle of Ra-223 administration and aBSI change from baseline to after 12 weeks (ΔBSI).
Median baseline PSA and aBSI were 42.8 ng/mL and 1.5%, respectively. Median OS was 20.7 months. Multivariate analysis showed that baseline aBSI was a significant prognostic factor for OS. The aBSI at 12 weeks after first Ra-223 administration also exhibited significant prognostic value for OS, while we found no evidence of prognostic value for ΔBSI.
Baseline aBSI may be a significant prognostic factor for OS in bone-metastatic CRPC patients treated with Ra-223.
本研究的目的是评估自动骨扫描指数（aBSI）作为接受镭-223（Ra-223）治疗的骨转移性去势抵抗性前列腺癌（mCRPC）患者总生存期（OS）的预后生物标志物。
我们纳入了42例接受Ra-223治疗的mCRPC男性患者。通过多因素分析研究aBSI作为独立预后因素的情况。此外，我们评估了首次给予Ra-223治疗12周后的aBSI的预后价值以及从基线到12周后的aBSI变化（ΔBSI）。
基线前列腺特异性抗原（PSA）和aBSI的中位数分别为42.8 ng/mL和1.5%。中位总生存期为20.7个月。多因素分析显示基线aBSI是总生存期的显著预后因素。首次给予Ra-223治疗12周时的aBSI对总生存期也具有显著的预后价值，而我们未发现ΔBSI具有预后价值的证据。
基线aBSI可能是接受Ra-223治疗的骨转移性CRPC患者总生存期的显著预后因素。
